<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01370876</url>
  </required_header>
  <id_info>
    <org_study_id>10CT006A</org_study_id>
    <nct_id>NCT01370876</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Oxaliplatin/5-FU in Patients With Recurrent or Metastatic Head and Neck Cancer</brief_title>
  <official_title>A Phase II Trial Evaluating Efficacy and Safety of OpatinÂ® (Oxaliplatin)/5-FU in Patients With Recurrent or Metastatic Head and Neck Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nang Kuang Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nang Kuang Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the objective response rate of oxaliplatin combined with 5-FU in patients with
      recurrent or metastatic head and neck cancer and to assess the safety profile of these
      treatment regimen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the objective response rate of oxaliplatin combined with 5-FU in patients with
      recurrent or metastatic head and neck cancer.

      To assess the safety profile of these treatment regimen. To evaluate the duration of response
      of oxaliplatin/5-FU.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    company policy
  </why_stopped>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>every 12 weeks</time_frame>
    <description>To evaluate the objective response rate of oxaliplatin combined with 5-FU in patients with recurrent or metastatic head and neck cancer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>Each patient will be followed for 30 days after the last dose of study medication</time_frame>
    <description>To assess number of participants with adverse events of these treatment regimen</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Cancer of the Head and Neck</condition>
  <condition>Neoplasms, Head and Neck</condition>
  <arm_group>
    <arm_group_label>Oxaliplatin/5-FU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Oxaliplatin will be administered as a 2-hour infusion first on Day 1, followed by 5-FU i.v. infusion for 48 hours (Day 1 and Day 2), repeated every 2 weeks, 4 weeks as a cycle.</description>
    <arm_group_label>Oxaliplatin/5-FU</arm_group_label>
    <other_name>Opatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have been histologically confirmed squamous cell carcinoma of the head
             and neck (SCCHN) except nasopharyngeal cancer.

          -  Patients must have recurrent or metastatic disease and for which curative surgery or
             radiotherapy do not exist or are no longer effective.

          -  Prior to entering the protocol treatment, it has to be more than 6 months interval
             between previous systemic chemotherapy and protocol treatment.

          -  The disease must have been measurable by computed tomographic (CT) scan or MRI (done
             within 30 days of study entry) and the diameter of the target tumor is at least more
             than 1 cm.

          -  Patients must be 20 years of age and 75 years of age.

          -  Patients must have an ECOG performance status score 2.

          -  Patient's hematologic function, liver function and renal function must meet the
             eligibility requirements.

          -  Patients must sign the informed consent.

        Exclusion Criteria:

          -  Patients with known hypersensitivity history to Platinum compounds or to
             5-Fluorouracil.

          -  Patients with brain metastases.

          -  Patients with bone metastases only.

          -  Patients with pregnancy or breast-feeding.

          -  Patient with CTC (NCI Common Toxicity Criteria) grade 2 peripheral neuropathy of any
             cause that is clinically detectable.

          -  Patients who have serious concomitant illness that might be aggravated by chemotherapy
             and other conditions which will be judged by physician's discretion.

          -  Patients who are receiving other anticancer cancer drug(s) for SCCHN.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chang Yi Fan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taipei Mackay Memorial Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Taipei Mackay Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>104</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2011</study_first_submitted>
  <study_first_submitted_qc>June 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2011</study_first_posted>
  <last_update_submitted>December 9, 2013</last_update_submitted>
  <last_update_submitted_qc>December 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2013</last_update_posted>
  <responsible_party>
    <name_title>Cancer Center, Head and Neck Cancer Team</name_title>
    <organization>Taipei Mackay Memorial Hospital</organization>
  </responsible_party>
  <keyword>Oxaliplatin</keyword>
  <keyword>Head and Neck cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

